Released: Tuesday 28th November 2017

 NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award

23 November 2017, Brussels: NovaBiotics, the clinical-stage anti-infectives biotechnology company, was named Most Innovative EU Biotech SME at EuropaBio’s 8^th annual SME Awards, recognising the Company’s innovation in tackling Antimicrobial Resistance (AMR) as one of our greatest global health challenges.

The EuropaBio Awards celebrate highly innovative small and medium sized enterprises from across Europe that have developed novel ways of meeting societal, technical, and environmental problems through the application of biotech. The panel who selected NovaBiotics as the winner of the ‘Red biotech’ award comprised biotech experts and leaders who understand the science, funding realities and broader European biotech ecosystem in which SMEs operate.

NovaBiotics is a leading innovator in the anti-infectives space and have gone back to the drawing board to develop a novel approach to antibacterial and antifungal drug design using ‘smart immunology’ and biology-led intelligent drug design. Its technology and business model has been validated through successful development, from concept to clinic, of two lead products and securing the most appropriate commercial collaborations to enable the delivery of these highly promising therapy candidates to markets of significant worth.

Dr Deborah O’Neil, Chief Executive Officer, said “We are thrilled to have been named as the Most Innovative EU Biotech at Wednesday night’s ceremony in Brussels in the Red Biotech (Healthcare) category. Being awarded such a prestigious, Europe wide award and in such an impressively strong field is fantastic recognition of our leading innovation in AMR and anti-infectives drug discovery. My sincere thanks go out to the prestigious panel of judges who made the decision based on our innovation and contribution to the global AMR crisis. I am also extremely proud that we accepted this award from the largest and most influential biotech industry group on the continent.”

EuropaBio Press Release available at https://www.europabio.org/cross-sector/publications/top-european-biotech-smes-announced-8th-edition-europabio-awards

[ENDS]

Notes for editors

For further information, interviews and photography, please contact Newgate Communications - novabiotics@newgatecomms.com, Sophie O’Donoghue, +44 (0)20 7680 6534

NovaBiotics

NovaBiotics Limited (“NovaBiotics” or the “Company”) is a private, UK-based anti-infectives focused biopharmaceutical company.  The Company has an advanced product portfolio of antimicrobial assets targeting large and important markets with significant unmet clinical needs. These include Lynovex, a novel multi-active orphan therapy for cystic fibrosis, Novexatin for the treatment of onychomycosis, a potential blockbuster outlicenced to Taro Pharmaceuticals, and Novamycin, a novel rapid acting antifungal for aspergillosis and other life-threatening yeast and mould infections. The Company is also developing earlier stage compounds from its proprietary antimicrobial peptide rational drug design platform.

Lynovex^®

Lynovex is a novel, highly differentiated therapy for the treatment of CF-associated lung disease.  The CF market is estimated at $6 billion and there is a clear need for effective treatment of the symptoms of CF-associated lung disease, the most critical clinical manifestation of this orphan disease.  Lynovex addresses the key treatment challenges through its unique triple mode of action: Antibacterial - addressing both current (e.g. Pseudomonas) and emerging/antibiotic insensitive (e.g. NTM and Burkholderia Spp) pathogen; Mucolytic - clear superiority to approved mucolytic therapeutics; Antibiofilm - addressing the key challenge of mucus build up within the airways of CF patients. 

Efficacy has been demonstrated through in vitro study, ex vivo (sputum) and a clinical phase IIa study. In addition, the Company has demonstrated that Lynovex dramatically enhances the effect of existing anti-infective drugs.  To that end, Lynovex is intended for use alongside existing standard of care therapies (SOCT) and to treat all CF disease genotypes. It is not a mutation-specific, CFTR-targeting intervention.